The U.S. Food and Drug Administration (FDA) this week approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe type I leukocyte adhesion deficiency (LAD-I). The autologous hematopoietic stem cell gene therapy addresses the underlying genetic cause of this ultra-rare, life-threatening pediatric immunodeficiency, offering a potentially curative alternative to high-risk allogeneic stem cell transplantation.
In-house lentiviral vector and cell processing capabilities; capacity for 20–30 patients annually initially
Competitive Landscape
First-mover advantage – no other LAD-I gene therapies in clinical development
Commercial Strategy:Center of Excellence model – treatment at specialized pediatric immunology/transplant centers; patient identification via newborn screening expansion advocacy
Global Expansion: EMA filing 2026–2027; Japan PMDA pathway for rare pediatric diseases
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch execution, manufacturing scale-up, and global regulatory expansion for Kresladi. Actual results may differ due to reimbursement negotiations for ultra-high-cost gene therapies, long-term durability data requirements, and competitive entry from allogeneic “off-the-shelf” cell therapy approaches.-Fineline Info & Tech
